Design of Novel Molecules that Regulate Sirtuins
Brandi D. Sanders
This technology provides a method for rational, structure-aided drug design to develop small molecules that target the regulatory nicotinamide binding site of Sir2 proteins. Sir2 modulators may be useful for the treatment of diabetes, obesity, Alzheimer’s, other neurodegenerative diseases, and diseases of aging.
U.S. Patent Application No. 12/023,287 (US-2008-0305496, published 12/11/2008); U.S. Patent Application No. 12/511,679 (US-2009-0326007, published 12/31/2009).
Wistar is seeking to collaborate with a corporate partner to use this technology to develop small molecule modulators of Sir2. An exclusive license or sponsored research to further develop the technology would be considered.
Sanders, B.D.; Zhao,K.; Slama, J.T.; Marmorstein, R.; (2007) “Structural basis for nicotinamide inhibition and base exchange in Sir2 enzymes”. Mol Cell 25: 463-472